Horehound — Benefits Deep Dive

White horehound — Marrubium vulgare, a woolly grey-green bitter in the mint family, and not to be confused with black horehound (Ballota nigra), a different plant with a different traditional use — is one of the very few folk cough remedies that survived intact into the modern confectionery aisle. Horehound candy and amber lozenges are a genuine piece of living folk pharmacy, still made, still sold, still bitter. Its marker constituent is the labdane diterpene marrubiin, alongside marrubenol and a supporting cast of flavonoids and bitter principles.

And here is the fact that belongs at the top rather than buried in a footnote: the United States Food and Drug Administration concluded that horehound had not been shown to be effective as an over-the-counter cough and cold ingredient, and it was removed from the approved monograph list. That is why horehound drops today are sold as candy or as dietary supplements rather than as cough medicine. It is a documented negative regulatory finding on one of the most traditional remedies in the Western repertoire, and almost nobody writing about horehound mentions it.

The interesting part is that this does not contradict Europe, where horehound herb holds a traditional-use herbal registration covering cough and its use as a bitter digestive. A traditional-use registration explicitly does not require efficacy trials — it requires a long documented history of use, plausible safety and plausible pharmacology. Once you know that, the American and European positions stop looking like a disagreement and start looking like answers to two different questions. These four deep dives work through the regulatory story, the better-founded bitter-digestive use and the awkward modern research that complicates it, the chemistry of marrubiin and its rodent metabolic file, and the specific safety considerations — blood pressure, pregnancy, dose, and the sugar in the candy.

Table of Contents

1. The Four Deep Dives
2. Horehound at a Glance
3. Research: The Regulatory Divide
4. Research: Bitters, Appetite and the Gut
5. Research: Marrubiin and Horehound Chemistry
6. Research: Metabolic and Cardiovascular Preclinical Work
7. Research: Safety, Pregnancy and Interactions
8. External Resources
9. Connections

The Four Deep Dives

1. Horehound for Cough, and Why the FDA Removed It — the negative American regulatory finding, the European traditional-use registration, and why both are correct.
2. Horehound as a Bitter: Digestion and Appetite — the cephalic-phase mechanism, the registered indication, and the contradictory human bitter-receptor data.
3. Marrubiin: Horehound's Chemistry and Metabolic Research — the chemistry, the calcium-channel mechanism, and the preclinical metabolic file read honestly.
4. Horehound Safety: Blood Pressure, Pregnancy and Dose — cardiovascular and glycaemic cautions, pregnancy, dose forms, and the sugar.

Horehound at a Glance

A one-screen summary, with each claim carrying its evidence tier. The detail sits behind the four cards above.

• Identity. White horehound, Marrubium vulgare, Lamiaceae. Square stems, wrinkled woolly grey leaves, whorls of small white flowers, intensely bitter. Not black horehound, Ballota nigra, which is a separate plant traditionally used as a mild sedative and for nausea.
• Marker chemistry. Marrubiin, a labdane diterpene lactone, formed largely from premarrubiin during drying; plus marrubenol, flavonoids including luteolin and apigenin derivatives, the phenylpropanoid verbascoside, tannins and a modest essential oil. Tier: well characterised chemistry.
• Cough, United States. Tier: NOT SHOWN EFFECTIVE. An explicit regulatory determination that horehound is not generally recognised as effective as an OTC cough and cold ingredient.
• Cough, Europe. Tier: traditional use only. Registered as an expectorant for cough associated with a cold, on the strength of long use rather than trials.
• Bitter digestive. Tier: traditional use only, with an established general mechanism. Registered for temporary loss of appetite and mild dyspeptic complaints; the cephalic phase and gut bitter receptors are real physiology, but the direction of effect on appetite is contested in human studies.
• Glucose and lipids. Tier: preliminary, animal only. Horehound infusions lowered glucose and improved lipids in diabetic rodents. Not a diabetes treatment; relevant chiefly as an interaction caution.
• Blood pressure and vessels. Tier: preliminary, mechanism named. Marrubenol acts as an L-type calcium channel blocker; extracts relaxed vessels and lowered blood pressure in hypertensive rats. Again a caution, not a treatment.
• Pain and inflammation. Tier: preliminary, rodent. Marrubiin reduced experimental oedema; extracts and marrubiin derivatives showed analgesia in animal models.
• Human trials. Tier: none adequate for any indication. This is the defining feature of horehound's evidence base.
• Main cautions. Pregnancy and breastfeeding; antihypertensive, antiarrhythmic and glucose-lowering medication; cardiac disease; active ulcer, gastritis, marked reflux or gallstones; Lamiaceae allergy; nausea and purgation at large doses; and the sugar load of the candy.

Research: The Regulatory Divide

The two positions that define how horehound may be sold, and the reason they are compatible. Citations are PubMed topic searches and agency landing pages rather than fixed identifiers.

• The American determination that horehound is not generally recognised as safe and effective for OTC cough and cold use is an agency action rather than a journal paper; the primary source is the U.S. Food and Drug Administration, whose pages on over-the-counter drug monographs and on ingredients removed from OTC products document the outcome. Detail on the cough page.
• The European Union herbal monograph on Marrubium vulgare herb, with its expectorant and digestive traditional-use indications, together with the assessment report behind it, is published by the European Medicines Agency.
• Reviews of the European traditional herbal medicinal product framework explain what a traditional-use registration requires — long documented use, plausible safety, plausible pharmacology — and what it explicitly does not require, namely efficacy trials. PubMed search
• Germany's Commission E monographs, the earlier European framework listing horehound as approved for coughs and bronchial complaints and for loss of appetite and dyspepsia, are frequently summarised in the review literature on Marrubium. PubMed search
• The literature on the demulcent and sweet-vehicle contribution to cough remedies, argued at length by Ronald Eccles among others, is what makes the negative finding easy to reconcile with generations of satisfied users. PubMed search

Research: Bitters, Appetite and the Gut

The mechanism is solid; the direction of effect is not. This is the most intellectually honest corner of horehound's file.

• Meyerhof W, Behrens M and colleagues on the human TAS2R bitter taste receptor family, its ligand profiles and its expression outside the mouth — the work that turned "bitter" from a folk category into a defined molecular stimulus. PubMed search
• Andreozzi P and colleagues, "The bitter taste receptor agonist quinine reduces calorie intake and increases the postprandial release of cholecystokinin in healthy subjects," Journal of Neurogastroenterology and Motility, 2015 — the clearest human result running against the traditional appetite-stimulant claim. PubMed search
• Deloose E and colleagues on intragastric denatonium benzoate, interdigestive gastric motility, hunger scores and ghrelin in healthy volunteers — bitter stimulation reduced motility and hunger. PubMed search
• Wicks D and colleagues, "Impact of bitter taste on gastric motility," European Journal of Gastroenterology and Hepatology, 2005 — delayed rather than accelerated gastric emptying. PubMed search
• Rezaie P and colleagues in Nutrients, asking whether preclinical findings on bitter substances translate into human outcomes for gastrointestinal function, energy intake and glycaemia — the explicit statement of the translation gap. PubMed search
• Cephalic-phase physiology — taste- and chewing-triggered gastric acid, pancreatic and gallbladder responses carried by the vagus — is the century-old foundation the bitter tradition rests on. PubMed search

Research: Marrubiin and Horehound Chemistry

• Popoola OK, Elbagory AM, Ameer F and Hussein AA, "Marrubiin," Molecules, 2013 — the dedicated review of the compound, its occurrence and its reported pharmacology. PubMed search
• Meyre-Silva C and Cechinel-Filho V, "A review of the chemical and pharmacological aspects of the genus Marrubium," Current Pharmaceutical Design, 2010 — the genus-level survey. PubMed search
• Aćimović M and colleagues, "Marrubium vulgare L.: a phytochemical and pharmacological overview," Molecules, 2020 — the most recent broad review, and the quickest way to see how preclinical the file is. PubMed search
• Amri B and colleagues, "Marrubium vulgare L. leave extract: phytochemical composition, antioxidant and wound healing properties," Molecules, 2017 — the flavonoid and antioxidant characterisation. PubMed search
• Work on marrubiin isolated from Leonotis leonurus by Mnonopi, Levendal, Frost and colleagues — important context, and a reminder that a great deal of marrubiin pharmacology was not generated on horehound at all. PubMed search

Research: Metabolic and Cardiovascular Preclinical Work

Every item here is rodent or in-vitro. None establishes a human benefit; several are better read as reasons for caution.

• Boudjelal A, Henchiri C, Siracusa L, Sari M and Ruberto G, "Compositional analysis and in vivo anti-diabetic activity of wild Algerian Marrubium vulgare L. infusion," Fitoterapia, 2012 — the most-cited glucose and lipid result. PubMed search
• El Bardai S, Wibo M, Hamaide MC, Lyoussi B, Quetin-Leclercq J and Morel N, "Characterisation of marrubenol, a diterpene extracted from Marrubium vulgare, as an L-type calcium channel blocker," British Journal of Pharmacology, 2003 — the named molecular mechanism, and the basis for the cardiovascular cautions. PubMed search
• El Bardai S and colleagues, "The vasorelaxant activity of marrubenol and marrubiin from Marrubium vulgare," Planta Medica, 2003, and "Pharmacological evidence of hypotensive activity of Marrubium vulgare and Foeniculum vulgare in spontaneously hypertensive rat," Clinical and Experimental Hypertension, 2001. PubMed search
• Stulzer HK and colleagues, "Antioedematogenic effect of marrubiin obtained from Marrubium vulgare," Journal of Ethnopharmacology, 2006 — the anti-inflammatory screening result. PubMed search
• de Souza MM and colleagues, "Analgesic profile of hydroalcoholic extract obtained from Marrubium vulgare," Phytomedicine, 1998, with Meyre-Silva C and colleagues on the analgesic potential of marrubiin derivatives in Il Farmaco, 2005. PubMed search
• Japanese work identifying a fatty acid constituent of a methanol extract of M. vulgare as a PPARγ agonist — a candidate metabolic mechanism located outside the diterpene fraction. PubMed search
• Searches for controlled human trials of horehound in metabolic or cardiovascular endpoints return nothing adequate. The absence is the finding. PubMed search

Research: Safety, Pregnancy and Interactions

• Reported adverse events, toxicity studies and case reports involving Marrubium vulgare are strikingly sparse; verifying that thinness is part of using the herb responsibly, because absence of reported harm is weaker evidence than it feels. PubMed search
• Reviews of herbal medicine use in pregnancy and of emmenagogue-classified herbs give the standard basis for horehound's pregnancy contraindication. PubMed search
• The herb-drug interaction literature on antihypertensive and glucose-lowering medication frames why a plausible pharmacodynamic addition matters even in the absence of quantified interaction studies. PubMed search
• Honey for acute cough in children has the best trial evidence of anything in the traditional horehound-and-honey preparation, with the standing caution against honey under one year of age. PubMed search
• Ballota nigra has its own separate literature and its own profile; safety information does not transfer between the two horehounds. PubMed search

Back to Table of Contents

External Resources

• U.S. Food and Drug Administration — primary source for the finding that horehound is not generally recognised as effective as an OTC cough and cold ingredient, and for the food-flavouring and dietary-supplement frameworks that horehound products are sold under instead.
• European Medicines Agency — the European Union herbal monograph and assessment report on Marrubium vulgare herb, and the framework documents defining traditional-use registration.
• PubMed — the biomedical literature index behind every citation on these pages.
• PubChem — structural records for marrubiin, marrubenol and horehound's flavonoids.
• National Center for Complementary and Integrative Health — plain-language evidence summaries and guidance on reading preclinical herbal research.
• LiverTox — the NIH database of drug- and herb-induced liver injury.

Connections

• All Herbs
• Horehound (main article)
• Horehound, Cough and the FDA
• Horehound as a Bitter
• Marrubiin Chemistry
• Horehound Safety
• Mullein
• Mullein Benefits
• Marshmallow Root
• Coltsfoot
• Elecampane
• Thyme
• Thyme Benefits
• Yarrow
• Yarrow Benefits
• Wormwood
• Dandelion
• Licorice
• Slippery Elm
• Fennel
• Peppermint
• Bronchitis
• Lung & Respiratory Health
• Functional Dyspepsia
• Hypertension
• Type 2 Diabetes

Safety and disclaimer. These pages are educational and are not medical advice. Horehound has not been shown to be effective as an over-the-counter cough medicine in the United States, and its European indications rest on long-standing traditional use rather than on clinical trials; every metabolic and cardiovascular finding described here is preclinical. Avoid horehound in pregnancy and while breastfeeding; avoid it with active peptic ulcer, gastritis, marked reflux or gallstones; skip it if you are allergic to mint-family plants; and use concentrated preparations cautiously and with your prescriber's knowledge if you take medication for blood pressure, heart rhythm or blood sugar, or have cardiac disease. Large doses cause nausea and can act as a purgative, and horehound candy is largely sugar. A cough lasting more than about three weeks, or unexplained appetite or weight loss, needs a clinician rather than a herb.

Back to Table of Contents